Silence Therapeutics plc
SLN
$7.35
$0.456.52%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -195.68% | 41.04% | -38.47% | -1,134.00% | 170.40% |
| Total Depreciation and Amortization | -19.29% | 3.31% | -1.33% | -9.21% | -0.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 91.99% | -93.32% | 204.14% | 67.40% | -295.12% |
| Change in Net Operating Assets | 84.07% | 412.19% | -141.18% | 201.64% | -1,576.85% |
| Cash from Operations | 37.09% | 57.47% | -302.74% | -34.63% | -90.13% |
| Capital Expenditure | 100.00% | 95.31% | 43.53% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -180.59% | 234.71% | -3,704.76% | 11.08% | 5,868.94% |
| Cash from Investing | -180.66% | 234.48% | -3,532.56% | 11.07% | 5,864.03% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -99.92% | -99.99% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 100.00% | -100.00% | -99.92% | -99.99% | -100.78% |
| Foreign Exchange rate Adjustments | 18.87% | -139.55% | 1,514.29% | 762.86% | -131.92% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -284.32% | 172.59% | -441.70% | -176.34% | 1,592.55% |